Посмотрите результаты терапии из Германии:

In the prospective German LISA trial, whose results were recently published, 1024 patients with thyroid nodules/goiter were treated for a year with:
>TSH-adapted levothyroxine (LT4), an
>LT4-iodide combination,
>iodide alone,
>or placebo (17).

After 3 months of treatment, the levothyroxine dose was adjusted so that the TSH value came into the target range (0.2–0.8 mU/L).

A nodular volume reduction of
21.6% was observed under LT4-iodide combination therapy, compared to a
5.2% reduction with placebo.

Combination therapy was superior to both
levothyroxine monotherapy (12.6% volume reduction) and
iodide monotherapy (9% volume reduction).

Over the same period of time, the patients’ thyroid volumes were reduced by 10% under LT4-iodide combination therapy, compared to 1.9% with placebo.

This is the first large-scale, placebo-controlled trial to demonstrate volume reduction in nodular goiter with levothyroxine–iodide treatment even without TSH suppression. Some practical questions remain to be addressed, including the long-term course of thyroid nodules after the end of treatment, the potential indication for switching to iodide monotherapy for long-term treatment, and the optimal target range for long-term TSH control to achieve a lasting reduction in nodular volume (17).

The advantages of drug therapy are low cost, non-invasiveness, and no need for hospitalization.

The disadvantages of drug therapy are its unclear mechanism of action, the lack of data on long-term success, iatrogenic hyperthyroidism, diminishing compliance over time, and inadequate effectiveness for large, nodular goiters.

[Ссылки доступны только зарегистрированным пользователям ]